Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection

被引:144
作者
Nos, Claude [1 ]
Lesieur, Benedicte [1 ]
Clough, Krishna B. [1 ]
Lecuru, Fabrice [1 ]
机构
[1] Hop Europeen Georges Pompidou, Dept Gynecol & Oncol Surg, Paris, France
关键词
breast carcinoma; sentinel lymph node biopsy; axillary dissection; blue dye;
D O I
10.1245/s10434-007-9450-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite the widespread use of the sentinel lymph node biopsy technique, many patients with invasive breast cancer still undergo an axillary lymph node dissection and are at risk of arm lymphedema. With the new awareness of lymphatic spread in the axillary nodes, it should be possible to define a new surgical approach between sentinel lymph node biopsy and complete axillary dissection, a procedure preserving specifically lymph nodes in relation to the arm. Methods: Twenty-one patients with an operable breast cancer requiring an axillary dissection underwent surgery with an attempt to separate nodes related to the breast from specific nodes related to the arm. After an injection of blue dye in the arm, the surgeon performed the axillary dissection trying to identify blue nodes and ducts in order to preserve lymphatic arm drainage (LAD). If the blue nodes were located in the normal axillary dissection, they were removed separately. Results: In 15 of 21 patients (71%), blue nodes in relation with LAD were identified. In 10 (47%) patients, it was possible to dissect the LAD with the preservation lymphatic ducts. In 10 patients, the LAD nodes were removed: none of them contained metastases, despite the fact that the non-LAD axillary nodes contained metastases in 7 of 10 cases. Conclusions: Identifying the LAD with blue dye injection in the arm is possible. A subsequent study can now begin to determine if this procedure is safe for patients and able to prevent lymphedema of the arm.
引用
收藏
页码:2490 / 2496
页数:7
相关论文
共 27 条
[1]  
Armer JM, 2004, LYMPHOLOGY, V37, P73
[2]   Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer [J].
Blanchard, DK ;
Donohue, JH ;
Reynolds, C ;
Grant, CS .
ARCHIVES OF SURGERY, 2003, 138 (05) :482-487
[3]  
BOLLA M, 1991, B CANC RADIOTHER, V78, P81
[4]   Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer [J].
Cox, CE ;
Pendas, S ;
Cox, JM ;
Joseph, E ;
Shons, AR ;
Yeatman, T ;
Ku, NN ;
Lyman, GH ;
Berman, C ;
Haddad, F ;
Reintgen, DS .
ANNALS OF SURGERY, 1998, 227 (05) :645-653
[5]   LYMPHATIC MAPPING AND SENTINEL LYMPHADENECTOMY FOR BREAST-CANCER [J].
GIULIANO, AE ;
KIRGAN, DM ;
GUENTHER, JM ;
MORTON, DL .
ANNALS OF SURGERY, 1994, 220 (03) :391-401
[6]  
Goffman Thomas E, 2004, Breast J, V10, P405, DOI 10.1111/j.1075-122X.2004.21411.x
[7]   Medium-term follow-up data after sentinel node biopsy alone for breast cancer [J].
Haid, A. ;
Knauer, M. ;
Koeberle-Wuehrer, R. ;
Ammann, K. ;
Koller, L. ;
Eiter, H. ;
Lang, A. ;
Wenzl, E. .
EJSO, 2006, 32 (10) :1180-1185
[8]  
HAMA Y, 2007, CANCER, V103, P23
[9]   Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity [J].
Hama, Yukihiro ;
Koyama, Yoshinori ;
Urano, Yasuteru ;
Choyke, Peter L. ;
Kobayashi, Hisataka .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 103 (01) :23-28
[10]  
HIDDEN G, 1990, J MAL VASCUL, V15, P149